<DOC>
	<DOCNO>NCT00102375</DOCNO>
	<brief_summary>The purpose study determine whether triple combination Carboplatin , Paclitaxel Topotecan superior clinical outcome treatment ovarian cancer compare combination Carboplatin Paclitaxel .</brief_summary>
	<brief_title>Paclitaxel , Carboplatin , Topotecan Patients With Ovarian Cancer</brief_title>
	<detailed_description>Carboplatin-Paclitaxel current standard first-line treatment advanced ovarian cancer . One option improve therapeutic result incorporation third , non-cross-resistant drug first line chemotherapy advance ovarian cancer . In two separate , single center phase II study , different combination three active agent ( Carboplatin , Paclitaxel Topotecan ) test . In study , Carboplatin Paclitaxel give standard dos schedule , follow sequentially Topotecan well tolerate dose 1.25 mg/m2/day give five day repeat every 21 day . The prolonged therapy associate cumulative toxicity compliance patient good . Study Hypothesis/Comparison : The triple combination ( Carboplatin/Paclitaxel/Topotecan ) yield superior outcome treatment first-line ovarian cancer compare combination Carboplatin + Paclitaxel</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically proven epithelial carcinoma ovary fallopian tube extraovarian papillary serous carcinoma extent ovary International Federation Gynecology Obstetrics ( FIGO ) stage IIBIV , regardless measurable nonmeasurable disease No prior chemo radiotherapy Adequate hematologic , renal hepatic function : ANC ≥ 1.5 x 10^9/L , Platelet count ≥ 100 x 10^9/L , Total bilirubin ≤ 1.5 x upper normal limit , Alkaline Phosphatase ≤ 3 x upper normal limit , Serum creatinine ≤ 1.25 upper normal limit , Estimated GFR ≥ 60 ml/min Performance status 02 ( ECOG ) Life expectancy must great 12 week Nonepithelial tumor mixed epithelial/nonepithelial tumor ( e.g . mixed Mullerian tumor ) tumor low malignant potential ( borderline tumor ) Prior treatment chemo radiotherapy Administration simultaneous chemotherapeutic drug hormonal therapy simultaneous radiotherapy study treatment period plan whole abdominal radiotherapy History congestive heart failure Symptomatic brain metastasis Complete bowel obstruction Dementia Active infection serious underlie medical condition Preexisting motor sensory neurologic pathology</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>first-line</keyword>
	<keyword>Topotecan</keyword>
</DOC>